Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Gravis, Gwénaëlle; Boher, Jean-Marie; Chen, Yu Hui; Liu, Glenn; Fizazi, Karim; Carducci, Michael A.; Oudard, Stéphane; Joly, Florence; Jarrard, David; Soulié, M.; Eisenberger, Mario; Habibian, Muriel; Dreicer, Robert; García, Jorge A.; Hussain, Maha; Kohli, Manish; Vogelzang, Nicholas J.; Picus, Joel; DiPaola, Robert S.; Sweeney, Christopher J.

doi:10.1016/j.eururo.2018.02.001

Cited by 208 publications

(139 citation statements)

References 26 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…The present study showed that the CHAARTED and LATITUDE risk criteria could apply to Japanese patients. Furthermore, prognoses in clinical trials including GETUG‐AFU 15, CHAARTED and LATITUDE were apparently worse than those in real‐world studies from the USA, Western Europe and Japan; whereas prognoses in the real‐world studies seem to be similar, with small differences (Table ). In particular, the difference in OS between clinical trials and the present study would be greater when age was adjusted, which might be due to differences in race and medical care for castration‐resistant prostate cancer.…”

mentioning

confidence: 97%

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

et al. 2018

View full text Add to dashboard Cite

mentioning

confidence: 97%

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

et al. 2018

View full text Add to dashboard Cite

“…When considering optimal systemic therapy for low‐volume and high‐volume disease in mCSPC, the panel reached a consensus that in low‐volume mCSPC, there is strong evidence that ADT + docetaxel does not provide an OS benefit beyond ADT alone; thus, ADT + AA is favored in the low‐volume setting. However, there was unanimous consensus that in high‐volume mCSPC, there is strong evidence of OS benefit for ADT + docetaxel 70,71 . Thus, both ADT + AA or ADT + docetaxel are equally preferred treatment options in the high‐volume setting (Table 4).…”

Section: Resultsmentioning

confidence: 99%

“…However, there was unanimous consensus that in high-volume mCSPC, there is strong evidence of OS benefit for ADT + docetaxel. 70,71 Thus, both ADT + AA or ADT + docetaxel are equally preferred treatment options in the highvolume setting (Table 4). These recommendations are in line with the NCCN guideline.…”

Section: The Role Of Adt In Salvage Therapymentioning

confidence: 99%

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

et al. 2020

View full text Add to dashboard Cite

Background For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk‐benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. Methods A 14‐member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. Results This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting. Conclusion The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate‐sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge.

show abstract

“…In contrast, neutropenia, febrile neutropenia, fatigue, and sensory neuropathies were the most commonly seen grade 3/4 toxicities in patients receiving docetaxel. New evidence has shown that patients with low-volume metastases did not benefit from ADT plus early docetaxel [48]. Therefore, further investigations should be aimed at evaluating whether docetaxel or abiraterone added to ADT can provide survival benefits for patients with major cardiovascular comorbidities.…”

Section: Discussionmentioning

confidence: 99%

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer

Fang

Hwang

et al. 2020

Cancers

View full text Add to dashboard Cite

Few studies have assessed the benefits of androgen deprivation therapy (ADT) in men with metastatic prostate cancer (PC; mPC) at an old age or with major cardiovascular conditions. A retrospective cohort consisted of 3835 men with newly diagnosed mPC from the Taiwan Cancer Registry of 2008–2014. Among them, 2692 patients received only ADT in the first year after the cancer diagnosis, and 1143 patients were on watchful waiting. The inverse probability of treatment-weighted Cox model was used to estimate the effects of ADT on all-cause mortality and PC-specific mortality according to age, and the status of congestive heart failure (CHF), coronary arterial diseases (CADs), and stroke at the baseline. After a median follow-up of 2.65 years, 1650 men had died. ADT was associated with a 17–22% risk reduction in all-cause and PC-specific mortality in men without stroke, CAD, or CHF in the 65–79-year group. The survival benefit diminished in men with any of these preexisting conditions. In contrast, ADT was not found to be associated with any survival benefit in the ≥80-year group, even though they did not present with any major cardiovascular disease at the baseline. Patients who had CHF, CAD, or stroke at the baseline did not show a survival benefit following ADT in any of the age groups. Men who have preexisting major cardiovascular diseases or are ≥80 years do not demonstrate a survival benefit from ADT for mPC. The risk–benefit ratio should be considered when using ADT for mPC in older men especially those with major cardiovascular comorbidities.

show abstract

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Cited by 208 publications

References 26 publications

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer

Contact Info

Product

Resources

About